The Global Breast Cancer Therapeutics Market, which stood at US$ 17,868.8 Mn in 2018, will reach [US$ 38,573.5 Mn] by the end of 2026. If these figures prove true, the global breast cancer therapeutics market will rise at a CAGR of 10.2% between 2018 and 2026.
Browse Complete Report Details @
North America to Remain Dominant on Account of Presence of Skilled Professionals
The increasing number of breast cancer cases all over the world is anticipated to boost the global breast cancer therapeutics market at promising rates, finds Fortune Business Insights in a new study. The study is titled, “Breast Cancer Therapeutics Market: Global Market Analysis, Insights, and Forecasts”.
The breast cancer treatment market in North America is currently leading the global landscape, supported by the presence of well-established healthcare infrastructure and rising uptake of advanced facilities in the region. In 2018, North America generated a revenue of US$ 8,033.8 Mn because of the increasing prevalence of breast cancer in the region.
In addition to this, the region boasts the presence of several leading market players and skilled professionals. Besides this, governments of developed nations such as Canada and the U.S. are providing health insurance for cancer diagnostics. Spurred by these factors the breast cancer therapeutics market is likely to flourish in North America to emerge dominant
- Targeted Therapy
- Ado-Trastuzumab Emtansine
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Cancer Type
- Hormone Receptor
- North America
- Asia Pacific
- Latin America
- Middle East & Africa